Therefore, these results highlight the importance of the Myc protein expression status in the prognostication of HIV-DLBCL lymphomas treated with EPOCH-based chemotherapy and pave the way for investigation of future drug combinations targeting Myc+ HIV-DLBCL. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.